Han M, Smith S O, Sakmar T P
Laboratory of Molecular Biology and Biochemistry, Howard Hughes Medical Institute, Rockefeller University, New York 10021, USA.
Biochemistry. 1998 Jun 2;37(22):8253-61. doi: 10.1021/bi980147r.
Rhodopsin is a member of the large family of G protein-coupled receptors (GPCR's). Constitutive activity of GPCR's, defined as ligand-independent signaling, has been recognized as an important feature of receptor function and has also been implicated in the molecular pathophysiology of a number of human diseases. Rhodopsin has evolved a unique mechanism to minimize receptor basal activity. The chromophore 11-cis-retinal, which acts as an inverse agonist in rhodopsin, is covalently bound to the receptor to ensure extremely low receptor signaling in the dark. In this study, we replaced Met257 in TM helix 6 of opsin with each of the remaining 19 amino acids. Only mutant opsin M257R failed to be expressed in COS-cell membranes. Each of the remaining 18 mutant opsins, with the exception of M257L, was significantly constitutively active. Two mutants in particular, M257Y and M257N, displayed very high levels of constitutive activity. In addition, the double-site mutants with substitutions of both Met257 and Glu113 in TM helix 3 tended to be much more constitutively active than the sums of the activities of the individual single-site mutants. Based on existing structural models of rhodopsin, we conclude that Met257 may form an important and specific interhelical interaction with a highly conserved NPXXY motif in TM helix 7, which stabilizes the inactive receptor conformation by preventing TM helix 6 movement in the absence of all-trans-retinal. Furthermore, we are able to show that the pharmacological properties of the large number (approximately 50) of mutant opsins that we have characterized to date support the two-state model of GPCR function. These results suggest that rhodopsin and other GPCR's share a common mechanism of receptor activation that involves specific changes in helix-helix interactions.
视紫红质是G蛋白偶联受体(GPCR)大家族的一员。GPCR的组成性活性,即不依赖配体的信号传导,已被认为是受体功能的一个重要特征,并且也与多种人类疾病的分子病理生理学有关。视紫红质进化出了一种独特的机制来最小化受体的基础活性。发色团11-顺式视黄醛在视紫红质中作为反向激动剂,与受体共价结合,以确保在黑暗中受体信号极低。在本研究中,我们用其余19种氨基酸分别替换了视蛋白第6跨膜螺旋(TM螺旋)中的Met257。只有突变视蛋白M257R未能在COS细胞膜中表达。其余18种突变视蛋白,除M257L外,均具有显著的组成性活性。特别是两个突变体M257Y和M257N,表现出非常高的组成性活性水平。此外,在第3跨膜螺旋中同时替换Met257和Glu113的双位点突变体往往比单个单点突变体活性之和更具组成性活性。基于现有的视紫红质结构模型,我们得出结论,Met257可能与第7跨膜螺旋中高度保守的NPXXY基序形成重要且特定的螺旋间相互作用,在没有全反式视黄醛的情况下,通过阻止第6跨膜螺旋移动来稳定无活性的受体构象。此外,我们能够证明,我们迄今已表征的大量(约50种)突变视蛋白的药理学特性支持GPCR功能的双态模型。这些结果表明,视紫红质和其他GPCR共享一种受体激活的共同机制,该机制涉及螺旋间相互作用的特定变化。